Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$231.35M$231.35M+4.7% vs Q2 2023 Net Income$93.25M$93.25M+24.7% vs Q2 2023 EPS Diluted$0.72$0.72+28.6% vs Q2 2023 Operating Income$117,235,000+24.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$53,212,000−22.3% Margins · derivedOperating margin50.7%+7.9 pt vs Q2 2023
Net margin40.3%+6.5 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 6, 2024 · 37 d after period end